Down 10% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and pharma stocks a median 6%.
−1Long-term trend
Follow INVA's trial news. Pro members can get an alert when Innoviva files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Margin down 10.9 points |
| Its score | Down:Lowest Quality Score since Oct 2025 |
| Latest filing | 8-K, Nov 4 |
After its last 4 reports it closed -2.1% on average, higher 2 of 4 times.
No shelf registration or at-the-market program on file in the last three years.
No open-market buys or sales by its officers or directors in their filings of the last year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
INVA is #55 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 55 |
Expected to report Wed Feb 24, after the close (in 107 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $106.1M, 2% less than a year ago; a loss of $1.03 a share, from a profit of $1.08.
“Net income: net loss of $73.9 million, or $1.03 basic loss per share, driven primarily by a decrease in fair value of equity and long-term investments.”
INVA's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| U.S. net product sales | at least $150 million |
Sales grew 4.1% a year over 5 years, fiscal 2020 to 2025.
Its share count fell 5.7% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | -3.1% | -9.5% | not yet |
| Aug 5, 2026 | +3.0% | +2.9% | +1.5% |
| May 6, 2026 | +4.3% | +1.2% | +2.8% |
Sales grew in five of the last seven years, to $411M in 2025. It made a profit in each of the eight years.
RSI 31.2, MACD below signal, below both averages. Not scored.
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: INVA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
“We anticipate that RELVAR ® /BREO ® ELLIPTA ® (FF/VI) and ANORO ® ELLIPTA ® (UMEC/VI) will compete with a number of approved bronchodilator drugs alone or in combination, including each other and drug candidates under development that are designed to treat asthma and COPD.”
INVA scores 0 today, which Breakaway calls Below Average. It is #55 of 90 in Pharma by Quality Score, with 1 of 14 chart checks firing. Down 10% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and pharma stocks a median 6%. Shares: 16.8% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
INVA scores 0 today, which Breakaway calls Below Average (0 to 5). That is #55 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind INVA's 0.
Expected to report Wed Feb 24, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. INVA closed higher after 2 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.